JP2023524054A - ベータコロナウイルスの予防と治療 - Google Patents

ベータコロナウイルスの予防と治療 Download PDF

Info

Publication number
JP2023524054A
JP2023524054A JP2022566176A JP2022566176A JP2023524054A JP 2023524054 A JP2023524054 A JP 2023524054A JP 2022566176 A JP2022566176 A JP 2022566176A JP 2022566176 A JP2022566176 A JP 2022566176A JP 2023524054 A JP2023524054 A JP 2023524054A
Authority
JP
Japan
Prior art keywords
seq
vaccine
unit
betacoronavirus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524054A5 (cg-RX-API-DMAC7.html
Inventor
ブルンスビク フレードリクセン アグネーテ
セケーリヤ モニカ
シュイェトゥーヌ カロリーネ
ノルヘイム グンヌステイン
ステューブスルー エリーサベト
Original Assignee
ナイコード セラピューティクス アルメン アクスイェ セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナイコード セラピューティクス アルメン アクスイェ セルスカプ filed Critical ナイコード セラピューティクス アルメン アクスイェ セルスカプ
Publication of JP2023524054A publication Critical patent/JP2023524054A/ja
Publication of JP2023524054A5 publication Critical patent/JP2023524054A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022566176A 2020-05-01 2021-05-03 ベータコロナウイルスの予防と治療 Pending JP2023524054A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA202070282 2020-05-01
DKPA202070282 2020-05-01
DKPA202070293 2020-05-06
DKPA202070293 2020-05-06
DKPA202070735 2020-11-05
DKPA202070735 2020-11-05
DKPA202070820 2020-12-08
DKPA202070820 2020-12-08
DKPA202170069 2021-02-15
DKPA202170069 2021-02-15
PCT/EP2021/061602 WO2021219897A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Publications (2)

Publication Number Publication Date
JP2023524054A true JP2023524054A (ja) 2023-06-08
JP2023524054A5 JP2023524054A5 (cg-RX-API-DMAC7.html) 2024-05-15

Family

ID=75870604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566176A Pending JP2023524054A (ja) 2020-05-01 2021-05-03 ベータコロナウイルスの予防と治療

Country Status (11)

Country Link
US (1) US20230165952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143210A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524054A (cg-RX-API-DMAC7.html)
KR (1) KR20230005962A (cg-RX-API-DMAC7.html)
CN (1) CN116096735A (cg-RX-API-DMAC7.html)
AU (1) AU2021262521A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176527A1 (cg-RX-API-DMAC7.html)
IL (1) IL297621A (cg-RX-API-DMAC7.html)
MX (1) MX2022013661A (cg-RX-API-DMAC7.html)
WO (1) WO2021219897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
LU102995B1 (en) * 2022-08-17 2024-02-19 PMCR GmbH Immunization against coronavirus
EP4572778A1 (en) * 2022-08-17 2025-06-25 Pmcr Gmbh Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
WO2024044747A2 (en) * 2022-08-25 2024-02-29 University Of Florida Research Foundation, Inc. Immunogenic composition and uses thereof
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
US20260193669A1 (en) 2022-11-09 2026-07-09 Nykode Therapeutics ASA Co-Expression of Constructs and Polypeptides
EP4651892A2 (en) * 2023-01-20 2025-11-26 Duke University Epitope-scaffold immunogens for pancoronavirus vaccines
CN121263427A (zh) * 2023-04-07 2026-01-02 国立大学法人大阪大学 滤泡辅助性T细胞诱导性SARS-CoV-2刺突蛋白的部分肽
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
CN119143850A (zh) * 2024-08-20 2024-12-17 复旦大学 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048936A1 (en) * 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) * 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
WO2021216954A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating or preventing virus infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048936A1 (en) * 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL. MOL. IMMUNOL., vol. 17, JPN6026017884, March 2020 (2020-03-01), pages 613 - 620, ISSN: 0005861935 *
FRONT. MICROBIOL., JPN6025022587, April 2020 (2020-04-01), pages 658, ISSN: 0005608990 *
INT. J. APPL. BIOL. PHARM., vol. 11(2), JPN6025022588, April 2020 (2020-04-01), pages 37 - 45, ISSN: 0005608989 *
UIO:LIFE SCIENCE, JPN6025049024, 2016, ISSN: 0005743290 *

Also Published As

Publication number Publication date
IL297621A (en) 2022-12-01
MX2022013661A (es) 2022-11-30
KR20230005962A (ko) 2023-01-10
US20230165952A1 (en) 2023-06-01
CN116096735A (zh) 2023-05-09
AU2021262521A1 (en) 2022-12-08
CA3176527A1 (en) 2021-11-04
BR112022021905A2 (pt) 2022-12-13
WO2021219897A1 (en) 2021-11-04
EP4143210A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
US20230165952A1 (en) Betacoronavirus prophylaxis and therapy
US20240067681A1 (en) Subunit vaccine for treatment or prevention of a respiratory tract infection
US9777045B2 (en) Immunogenic compositions and methods
AU2021273827A1 (en) SARS-CoV-2 vaccines
Reginald et al. Development of peptide vaccines in dengue
EP3950705A1 (en) Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
US20250109175A1 (en) Recombinant gp120 protein with v1-loop deletion
JP2025510320A (ja) エピトープの組合せ及びその使用、ワクチン構築物、免疫応答を誘導する方法、エピトープを特定する方法
US20250339509A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
WO2023018817A1 (en) Truncated influenza neuraminidase and methods of using the same
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
KR20240110821A (ko) SARS-CoV-2로 인한 질병의 예방적 및 치료적 처치에 사용하기 위한 면역원성 작제물 및 백신
CN121574211A (zh) 一种新型冠状病毒重组亚单位抗原及其制备方法和在疫苗中的应用
Mashhadi et al. Immunoinformatics Approach for Designing an HPV Epitope-Based Vaccine Candidate Harboring Built-in Adjuvants
CN118742321A (zh) 用于预防性和治疗性治疗由SARS-CoV-2引起的疾病的免疫原性构建体和疫苗
WO2023020637A1 (es) Antigenos quimericos para el control de coronavirus y composiciones que los comprenden
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260519